- Subject
- Nutrition
- Filed
- Source
- Joseph Davis
- Loans
- 571
Alzheimer’s Brain Changes May Follow Different Timelines in Women and Men
A study of 332 people found different patterns of brain change by sex, raising questions about how cognitive test scores are interpreted.

A cognitive screening score may not tell the whole story of brain changes associated with Alzheimer’s disease, a study of 332 people suggests. Researchers at Georgia State University found that brain structure appeared to change at different stages in women and men. The findings raise questions about whether a screening result has the same meaning for everyone, but they don’t establish that current tests routinely miss Alzheimer’s in women.

Published in Brain Communications, the study examined brain scans from people who were cognitively healthy, had mild cognitive impairment (MCI), or had Alzheimer’s disease. Because it compared people at different stages, it offers a snapshot of patterns across those groups rather than tracking each participant’s brain over time. The results point to possible differences in how brain changes and cognitive performance relate to one another.
Different patterns across disease stages
In men, the researchers observed more brain shrinkage in the transition from healthy cognition to MCI, followed by comparatively stable measurements at later stages. In women, brain structure appeared relatively stable earlier, with steeper and more widespread decline between MCI and Alzheimer’s disease. These group-level patterns don’t predict how the disease will progress in any one person.
The analysis found significant sex-related differences in 10 brain regions, including areas in the frontal and temporal lobes. These regions contribute to functions such as memory, language, and planning. During Alzheimer’s progression, women also showed greater reductions in key areas, including the left frontal lobe.

The team also found that women’s cognitive scores were associated with a wider range of brain regions than men’s scores. One possible interpretation is that women may draw on more brain areas to maintain performance while structural changes are developing. That explanation remains a hypothesis: the study found a relationship between brain measures and scores, but it did not show that this broader activity causes women to perform better or delays symptoms.
What the findings say about screening
The Mini-Mental State Examination (MMSE) is a 30-point screening test used to assess cognitive function. The source describes it as being administered in the same way to women and men. Georgia State University study senior author Mukeshwar Dhamala, a professor of physics and neuroscience, said that a woman with MCI could receive a reassuring MMSE score while still having brain changes that the score does not capture. He suggested that screening results may need to be interpreted with sex-related differences in mind.
That is a reason to examine the limits of a single score, not proof that the MMSE fails women as a group. The study did not test a revised screening method, establish sex-specific score thresholds, or show that changing how clinicians interpret results improves diagnosis. A screening test is one part of an assessment; results need to be considered alongside a person’s concerns, history, and other clinical information.

The researchers’ findings also don’t mean that a normal score confirms underlying disease or that a particular pattern of brain change will lead to Alzheimer’s. The study compared scans and cognitive scores across stages, and its results need to be confirmed and tested in further research before they can guide changes to routine assessment.
Possible biological explanations
The study raises questions about why the observed patterns might differ. The article discusses several possible contributors, while noting that these mechanisms were not established by the brain-scan analysis itself.
- Hormones: Estrogen has effects on the brain, and levels change around menopause. Whether these changes help explain the differences observed in the study remains uncertain.
- Genetics: APOE-ε4 is a known genetic risk factor for Alzheimer’s. The article raises the possibility that its effects may interact with sex-related biology, but this study does not settle how that interaction works.
- Brain networks: Greater reliance on a wider set of brain regions could help explain why cognitive performance and structural changes do not always move in step. Researchers would need additional evidence to determine whether this is a form of compensation and how it changes as disease progresses.
These possibilities support research that accounts for sex differences when studying Alzheimer’s. They don’t yet show that hormones, genetic factors, or network activity caused the patterns in this sample. More work is needed to understand how these factors relate to disease timing, vulnerability, and test performance.
Practical context and what comes next
For people concerned about memory or other changes in thinking, one test score should be understood in context. A conversation with a healthcare professional can help clarify what a screening result does and doesn’t show, especially when concerns continue or affect daily life. Family history or questions about genetic risk can also be discussed with a clinician; the study does not establish who should seek genetic testing.
The research does not support a new screening protocol or a specific intervention for women in midlife or around menopause. It does support asking whether assessments and future studies capture differences in how brain structure and cognitive scores relate across sexes. Dhamala described a longer-term possibility: more sex-informed interpretation of diagnosis and biomarkers, and research trials designed with differing disease timing and brain vulnerability in mind.
For now, general measures associated with brain health include managing blood pressure, cholesterol, and blood sugar, and staying physically and mentally active. These are broad health considerations, not treatments for Alzheimer’s and not proof that a person can prevent the disease. The central finding is narrower: in this sample, women and men showed different patterns of brain change across disease stages, and a screening score may not reflect every aspect of that picture.